Skip to main content
Figure 4 | BMC Pharmacology

Figure 4

From: Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779

Figure 4

Improved survival and decreased tumor growth in nude mice bearing Tsc2-/- tumors due to treatment with either CCI-779 or rapamycin. a) Average tumor growth over time for indicated treatment cohorts. b) Survival curve for indicated treatment cohorts. Mantel-Cox logrank analysis shows improved survival in all treatment cohorts relative to untreated. c) Data shown in table format. P values listed are in comparison to the untreated cohort.

Back to article page

BMC Pharmacology

ISSN: 1471-2210